Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Maetrics announces new president
March 23, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing maetrics, steve cottrell
Maetrics has confirmed that Steve Cottrell, previously its vice president of sales, will now assume the role of president at …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
Lilly and Hanmi enter immunological therapy pact
March 20, 2015Research and Development, Sales and Marketing HM71224, Korea, Sjögren, hanmi, immunological, lilly
Eli Lilly and Korean-based pharma firm Hanmi have entered a collaboration agreement to develop and commercialise an immunological therapy. The …
Budget 2015: £1.25 billion boost for mental health services
March 20, 2015Sales and Marketing Budget, Cameron, Miliband, NHS, Osborne, UK
Senior NHS figures have hit out at Chancellor George Osborne’s failure to lay out any specific plans concerning the future …
GSK and Theravance see FDA nod for asthma indication
March 20, 2015Sales and Marketing Advair, AstraZeneca, Dulera, FDA, Foradil, GSK, Merck, Symbicort, Theravance, asthma, breo, budesonide/formoterol fumarate dihydratem, ellipta, fluticasone propionate, formoterol fumarate, mometasone/formoterol
An FDA panel has recommended the approval of asthma treatment Breo Ellipta in adults – but voted against supporting its …
Actavis gains new Allergan directors
March 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Michael Gallagher, Peter McDonnell
Ireland, Dublin-based pharma firm Actavis has added former Allergan members Michael Gallagher and Dr Peter McDonnell to its board of …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Breast cancer treatment market booming
March 19, 2015Research and Development, Sales and Marketing Frost, Herceptin, Kadcyla, Roche, breast cancer, oncology, targeted, tykerb
The increased use of combined targeted therapies for breast cancer is set to lift the market and improve progression-free disease …
AstraZeneca and Daiichi team up for constipation drug
March 19, 2015Sales and Marketing AstraZeneca, Daiichi, Movantik, constipation, naloxegol, oic
AstraZeneca and Daiichi Sankyo have signed a deal worth around $825 million to jointly commercialise constipation drug Movantik in the …
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
Teva and Ignyta shake hands in oncology deal
March 19, 2015Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology
Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …
MISSION hires chief business officer from Medivir
March 19, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing medvir, mission, paul wallace
UK, Cambridge-based cancer biotech MISSION Therapeutics has appointed Dr Paul Wallace as its chief business officer. Having worked in business …
Pharma to profit from Obama reforms
March 18, 2015Sales and Marketing FDA, GlobalData, Obama, US, healthcare, insurance
President Obama’s healthcare reforms will drive massive growth in the US pharma market a new report is predicting. The size …
Valeant sprints ahead of Endo to secure Salix
March 18, 2015Sales and Marketing Actavis, Canada, Endo, Valeant, Xifaxan, methylnaltrexone, rifaximin, salix
Salix Pharmaceuticals has accepted an improved $11.1 billion takeover swoop from Valeant Pharmaceuticals to beat rival bidder Endo International. The …
AstraZeneca buoyed by late-stage trial success
March 18, 2015Sales and Marketing AstraZeneca, copd. asthma, formoterol fumarate, glycopyrronium, ptoo3, respiratory
AstraZeneca’s investigational respiratory drug has posted positive results in a Phase III trial in people with COPD, having found it …
The 2015 European Life Sciences Industry Survey on Customer Data
March 18, 2015Dear Colleague, You are invited to take part in the 2015 European Life Sciences Industry Survey on Customer Data. Your …
GSK premature babies drug starts late-stage trials
March 18, 2015Sales and Marketing GSK, Retosiban, atosiban, babies, birth, oxytocin, premature
GlaxoSmithKline has initiated Phase III studies to evaluate the safety and efficacy of an investigational treatment for babies born prematurely. …
Catalent Pharma Solutions names new unit head
March 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing catalent pharma solutions, sharon johnson
UK pharma and healthcare products firm Catalent Pharma Solutions has picked its senior VP Sharon Johnson of the company’s quality …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
